


Bergapten

Cat. No.:	HY-N0370		
CAS No.:	484-20-8		
Molecular Formula:	C ₁₂ H ₈ O ₄		
Molecular Weight:	216.19		
Target:	Cytochrome P450; Autophagy		
Pathway:	Metabolic Enzyme/Protease; Autophagy		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	2 years
		-20°C	1 year



SOLVENT & SOLUBILITY

In Vitro

DMSO : 20 mg/mL (92.51 mM; Need ultrasonic)
 H₂O : < 0.1 mg/mL (ultrasonic) (insoluble)

	Solvent Concentration	Mass		
		1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM	4.6256 mL	23.1278 mL	46.2556 mL
	5 mM	0.9251 mL	4.6256 mL	9.2511 mL
	10 mM	0.4626 mL	2.3128 mL	4.6256 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
 Solubility: 1 mg/mL (4.63 mM); Suspended solution; Need ultrasonic
- Add each solvent one by one: 10% DMSO >> 90% corn oil
 Solubility: ≥ 1 mg/mL (4.63 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

Bergapten is a natural anti-inflammatory and anti-tumor agent. Bergapten is inhibitory towards mouse and human CYP isoforms.

IC₅₀ & Target

CYP^[1]

In Vitro

There is decreased N-acetyltransferase (NAT) activity in SC-M1 cells at concentrations of Bergapten (5-Methoxypsoralen, 5-MOP) from 0.05 mM to 25 mM, but no obvious dose-dependent effect is found between these doses (r=0.5687). In COLO 205 cells, there is decreased NAT activity at low doses of Bergapten (0.05 mM and 0.5 mM) and increased NAT activity at a high dose (50 mM). Bergapten induces a dosedependent effect in our experimental concentrations on COLO 205 cells (r=0.8912);

a promotion effect at a higher dose (50 mM) and an inhibition effect at lower doses (0.05-0.5 mM), while the concentrations 5-25 mM has no significant difference compared with the control regimen^[1]. Bergapten (5-Methoxypsoralen) exerts inhibitory effects on diabetes-related osteoporosis via the regulation of the PI3K/AKT, JNK/MAPK and NF-κB signaling pathways in osteoprotegerin knockout mice. Bergapten has also been shown to significantly inhibit the production of pro-inflammatory cytokines. Bergapten exhibits the ability to significantly inhibit RANKL-RANK signaling transduction, and to suppress the activation of the PI3K/AKT, JNK/MAPK and NF-κB signaling pathways, thus protecting trabecular structure and decreasing osteoclastogenic differentiation^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

The metabolic activity of NAT of the rat colon is higher than that of the stomach, and Bergapten (5-Methoxypsoralen, 5-MOP) causes a decrease of AF concentration in the stomach at the 24-h time-period. The concentrations of AAF in the stomach and colon are low. Although DMSO (solvent) influenced the metabolism of AAF, compared with the control regimen, Bergapten still causes an increase in the further metabolism of AAF, and a decrease in the concentration of AAF in the stomach at 24 h, and in the colon during the 24- to 72-h time-period^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

PROTOCOL

Cell Assay ^[1]

The human colon adenocarcinoma cell line (COLO 205, from a 70-year-old male Caucasian) are placed into 75-cm² tissue culture flasks and grown in RPMI1640 medium, supplemented with 10% fetal bovine serum, containing penicillin and streptomycin (100 µg/mL) and 1 mM glutamine, at 37°C in a humidified atmosphere of 5% CO₂ and 95% O₂. The human stomach adenocarcinoma cell line are placed into 75-cm² tissue culture flasks and grown in RPMI 1640 medium, supplemented with 10% fetal bovine serum, containing penicillin and streptomycin (100 µg/mL) and 1 mM glutamine, at 37°C in a humidified atmosphere of 5% CO₂ and 95% O₂. SC-M1 and COLO 205 cells are treated with different concentrations of Bergapten (0.05, 0.5, 5, 10, 25 and 50 mM) and incubated for 72 h for the dose-effect study of Bergapten on NAT activity. To determine the time-course effect of 0.5 mM Bergapten on NAT activity, the cells are incubated at 37°C and harvested at 12, 24, 48 and 72 h, respectively. Bergapten is dissolved in DMSO and the final concentration of vehicle is <0.1%. Only DMSO (solvent) is added for the control regimen^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration ^[1]

Rats^[1]

Seventy-two male Sprague-Dawley (SD) rats, weighing approximately 200 g are used. A total of 72 rats are subjected to 3 different regimens, each regimen divided into 4 groups with 6 rats in each group. Gastric intubation is used for delivery of the test compounds into each animal. The first regimen received 1 mL Bergapten (dissolved in DMSO) at a dose of 0.5 mmol per Kg of body weight. Regimen 2, the control regimen, received only 1 mL solvent (DMSO), without any Bergapten. Regimen 3, the contrast regimen, received nothing at that time. Twenty-four h later, all of the rats from the 3 regimens received 1mL AF (dissolved in DMSO) at a dose of 0.3 mmol per Kg of body weight. The groups are divided by different collecting time: 12, 24, 48 and 72 h after AF administration, and then the animals are transferred to individual metabolism cages. The stomachs and the colons of the rats from each regimen are collected and are immediately extracted with ethyl acetate/methanol (95:5). The solvent is evaporated and the residue redissolved in methanol and assayed for AF and AAF by HPLC.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

- Acta Pharmacol Sin. 2023 May 4.
- bioRxiv. 2023 Jun 15.
- bioRxiv. 2023 Jun 3.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Lee YM, et al. Effects of 5-methoxypsoralen (5-MOP) on arylamine N-acetyltransferase activity in the stomach and colon of rats and human stomach and colon tumor cell lines. *In Vivo*. 2005 Nov-Dec;19(6):1061-9.

[2]. Li XJ, et al. Bergapten exerts inhibitory effects on diabetes-related osteoporosis via the regulation of the PI3K/AKT, JNK/MAPK and NF- κ B signaling pathways in osteoprotegerin knockout mice. *Int J Mol Med*. 2016 Dec;38(6):1661-1672.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA